Tempus AI Stock 2025 Latest Price, Growth Outlook, and Investment Insights for TEM
April 17, 2025 2025-04-17 1:54Tempus AI Stock 2025 Latest Price, Growth Outlook, and Investment Insights for TEM
Tempus AI Stock 2025 Latest Price, Growth Outlook, and Investment Insights for TEM
Tempus AI Stock: Explore Tempus AI (TEM) stock’s 2025 performance, live share price, and growth outlook. Learn about Tempus AI’s innovations in healthcare, recent financials, analyst ratings, and how to invest in TEM from India or globally. Stay updated on the future of AI-driven healthcare stocks
Tempus AI Stock (TEM) in 2025: Growth, Volatility, and the Future of Healthcare AI
#Tempus AI (NASDAQ: TEM) is making waves in the healthcare technology sector, leveraging artificial intelligence to revolutionize precision medicine and patient care. If you’re considering investing in Tempus AI stock or just want to understand why it’s attracting so much attention in 2025, this blog post breaks down the latest trends, forecasts, and what makes Tempus AI a standout in the AI-driven healthcare space.
What Does Tempus AI Do?
Tempus AI specializes in using artificial intelligence to analyze clinical and molecular data, helping doctors make more informed decisions and deliver personalized treatments. Its business model combines three main segments:
- Genomics: High-throughput sequencing and AI-powered diagnostics, especially in oncology.
- Data & Services: Licensing de-identified clinical and molecular data to pharmaceutical and biotech companies for research and drug development.
- Apps: AI-driven tools for physicians and patients, including clinical trial matching and personalized health insights8.
Recent acquisitions, like Ambry Genetics and Deep 6 AI, have expanded Tempus’s capabilities in genomics and clinical trial recruitment, strengthening its position as a leader in healthcare AI8.
Tempus AI Stock Performance in 2025
- Current Price (April 2025): Around $41–$43 per share19
- 52-Week Range: $22.89 – $91.4511
- Market Cap: ~$7.8 billion11
- 2025 Revenue Guidance: $1.24 billion (up 79% year-over-year)46
- Adjusted EBITDA (2025): Projected at $5 million, a major improvement over 202446
Recent Trends:
- The stock surged nearly 40% year-to-date as of March 2025, outperforming the broader medical and tech sectors23.
- After a strong rally, shares experienced volatility following a Q4 2024 earnings miss and cautious 2025 guidance, but have since rebounded on news of strategic acquisitions and partnerships27.
- Institutional investors have shown strong interest, with over 65% of the float held by institutions1113.
Analyst Ratings and Price Targets
| Analyst Firm | Rating | Price Target ($) |
|---|---|---|
| Morgan Stanley | Buy | $60 |
| TD Cowen | Buy | $74 |
| Loop Capital | Buy | $52 |
| Needham | Buy | $56 |
| Wolfe Research | Outperform | $60 |
| JP Morgan | Neutral | $55 |
| BofA Securities | Neutral | $54 |
| Guggenheim | Buy | $74 |
- Average 12-Month Target: $61.18 (range: $48–$74)1210
- 2025 Share Price Forecast: Most experts expect a range of $50–$70 by year-end, with bullish scenarios reaching $741112.
Growth Drivers for Tempus AI
- AI-Powered Diagnostics: Tempus’s AI tools are gaining traction in oncology, cardiology, and mental health, driving higher test volumes and data licensing revenue8.
- Strategic Acquisitions: The addition of Ambry Genetics and Deep 6 AI expands Tempus’s reach in genomics and clinical trials, opening new revenue streams8.
- Strong Partnerships: Renewed multi-year deals with Google and major pharmaceutical companies support Tempus’s data and AI infrastructure68.
- Market Leadership: Tempus’s proprietary multimodal dataset and high client retention (140%) create high entry barriers for competitors58.
Risks and Volatility
- Stock Volatility: Shares have been highly volatile, with sharp drops after earnings misses and market corrections713.
- Short Interest: High short interest (up to 25%) has contributed to price swings13.
- Profitability Timeline: While revenue is growing rapidly, consistent profitability is expected by 202613.
- Bearish Sentiment: Some technical indicators and forecasts suggest short-term downside risk, with a bearish sentiment and a price prediction as low as $28.83 by May 20259.
Is Tempus AI Stock a Good Buy in 2025?
Pros:
- Leading position in healthcare AI and precision medicine
- Rapid revenue growth and expanding market share
- Strong institutional backing and strategic partnerships
- High client retention and recurring revenue
Cons:
- High volatility and short-term uncertainty
- Not yet consistently profitable
- Competitive and regulatory risks in healthcare and AI
Expert Consensus: Most analysts rate Tempus AI as a “Moderate Buy” for long-term investors who can handle volatility and are bullish on the future of AI in healthcare1213.
Conclusion
Tempus AI is at the forefront of the healthcare AI revolution, with a unique business model that combines genomics, data, and AI-driven applications. While the stock is volatile and faces short-term risks, its long-term growth prospects remain strong thanks to rapid revenue growth, strategic acquisitions, and a growing role in precision medicine. For investors seeking exposure to the future of healthcare technology, Tempus AI is a stock worth watching in 2025 and beyond.
- Toyota Rumion: किफायती 7-सीटर एमपीवी, दमदार फीचर्स और बेहतर माइलेज
- 8th Pay Commission News: फिटमेंट फैक्टर, सैलरी बढ़ोतरी और लागू होने की संभावित तारीख
- Sanjay Passi: छोटे परिवार से 2,690 करोड़ के ऑटोमोबाइल साम्राज्य तक की प्रेरणादायक कहानी
- Systematic Investment Plan News: SIP क्या है? सिस्टमेटिक इन्वेस्टमेंट प्लान से करें स्मार्ट निवेश – पूरी जानकारी हिंदी में
- Sikandar Box Office Collection: सलमान खान की फिल्म ने 18 दिन में कमाए 109 करोड़, हिट या फ्लॉप?
- Samsung Galaxy S24 Ultra: की कीमत में भारी गिरावट अब सिर्फ ₹84,999 में पाएं प्रीमियम फ्लैगशिप स्मार्टफोन
- Sikandar Movie Collection: सिकंदर बॉक्स ऑफिस कलेक्शन 2025 सलमान खान की फिल्म ने कमाए 109 करोड़ रुपये, हिट या फ्लॉप?
- Silver Price Today Jaipur: आज का चांदी का भाव जयपुर 2025 | ताज़ा रेट और बाजार का ट्रेंड
